

Study of the regulatory promoter polymorphism (–938C>A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran

Sepideh Esfahani Moghaddam, Ali Barzegar, Novin Nikbakhsh¹

Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Sari, ¹Department of Surgery, School of Medicine, Babol University of Medical Sciences, Babol, Iran

Background: The incidence rate of breast cancer has been dramatically increasing since the last decade in Iran, and it is now one of the most common female malignant tumors. B-cell lymphoma 2 (BCL2) family is the most important regulator of apoptosis, and –938C>A single nucleotide polymorphism (SNP) of *BCL2* gene promoter has been demonstrated to influence breast cancer susceptibility. In this research, we study the effect of –938C>A allelic variants on breast cancer risk in Mazandaran province at the North of Iran. **Materials and Methods:** This analysis performed on 120 breast cancer patients who underwent surgery in some referenced hospitals at Mazandaran province along with 130 healthy individuals as a control. DNA extracted from peripheral blood samples was applied in polymerase chain reaction-single-strand conformation polymorphism analysis to determine –938C>A genotype. The association of the –938C>A genotype and breast cancer risk as well as clinicopathological characters were analyzed by logistic regression method. **Results:** Results showed that genotype frequency of AA, AC, and CC genotypes was 10%, 62%, and 28% for case and 28%, 50%, and 22% in control group, respectively. In the logistic regression model, *BCL2* – 938C/A variant genotype AA was associated with a decreased risk of breast cancer ($P = 0.041$) by 0.31-fold (odds ratio = 0.31, confidence interval = 0.091–0.909) compared to CC genotype. However, no significant association found between –938C>A genotype and clinicopathological characters. **Conclusion:** The study showed that AA genotype of *BCL2* gene (–938C>A) is associated with decreased susceptibility to breast cancer. Hence, investigating the –938C>A SNP of *BCL2* gene promoter could be an appropriate molecular marker to determine individual sensitivity to breast cancer.

Key words: –938C>A, B-cell lymphoma 2, breast cancer, polymerase chain reaction-single-strand conformation polymorphism, polymorphism

How to cite this article: Esfahani Moghaddam S, Barzegar A, Nikbakhsh N. Study of the regulatory promoter polymorphism (–938C>A) of B-cell lymphoma 2 gene in breast cancer patients of Mazandaran province in Northern Iran. *J Res Med Sci* 2017;22:21.

INTRODUCTION

Breast cancer is the most prevalent malignancy and the causal agents of 19% of cancer-related death among women worldwide.^[1-3] The incidence rate of breast cancer has been dramatically increasing since the last decade, and with the age-standardized incidence rate of 28.25% in 100,000 women, it is now the most frequent malignancies among Iranian women.^[4] Reports show

that Iranian breast cancer cases are approximately one decade younger than their Western counterparts.^[5] Epidemiological studies defined various risk factors of breast cancer including genetic mutations, reproductive history, and environmental carcinogens in different population with ethnic and geographical variations.^[6-8] The genotypic variants specially those play roles in apoptosis or cell proliferation have also been reported to be involved in breast carcinogenesis. Apoptosis or programmed cell death occurs normally during development as a homeostatic mechanism to maintain

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

Access this article online	
Quick Response Code:	Website: www.jmsjournal.net
	DOI: 10.4103/1735-1995.200269

Address for correspondence: Dr. Ali Barzegar, Department of Basic Sciences, Sari Agricultural Sciences and Natural Resources University, Km 9 Darya Boulevard, P.O. Box 578, Sari, Iran. E-mail: alibar647@yahoo.com

Received: 07-04-2016; **Revised:** 01-11-2016; **Accepted:** 21-11-2016

cell populations in tissues.^[9] Inappropriate apoptosis either too little or too much has the effective role in cancer progress and metastasis.^[10,11] Apoptosis can be achieved through two different pathways including death receptor and mitochondrial pathway.^[12] The B-cell lymphoma 2 (*BCL2*) family proteins as the most important regulator of mitochondrial pathway include both proapoptotic members such as *BCL2*-associated X protein (*Bax*) and *BAX*-like death factor (*Bak*) and antiapoptotic/antiproliferative members such as *BCL2* itself and *BCL-xL*.^[13] *BCL2* gene which is placed on 18q21.3 consists of three exons and two introns coding for a 25 KDa protein.^[14] Despite the antiapoptotic property of *BCL2* gene, conflicting results have been acquired regarding to the association of its expression level and patient's survival and seems to be tissue specific.^[15-17] *BCL2* gene expression is regulated through alternative promoters including P1 and P2 having distinct regulatory roles. The P1 promoter has positive regulatory effect on *BCL2* gene expression, whereas P2 promoter located 1400 bp upstream of the translation initiation site modulates negative regulatory effect of *BCL2* gene expression which is exerted through P1 promoter.^[18] Single nucleotide polymorphisms (SNPs) of *BCL2* genes have been reported to be involved in several cancer types including chronic lymphocytic leukemia,^[19,20] prostate cancer,^[21] ovarian cancer,^[22] breast cancer,^[23] renal cancer,^[24] oropharyngeal squamous cell carcinoma,^[25] and sporadic medullary thyroid carcinoma.^[26] The -938C>A SNP in P2 promoter of *BCL2* gene was initially reported by Park *et al.*, through sequencing of this region in 24 DNA samples of Korean females.^[27] The association between -938C>A genetic variants and cancer progression was subsequently studied through investigation of several cancers in different population. Nückel *et al.* showed that - 938C allele is significantly associated with an increase in P2 promoter activity which inversely decreases *BCL2* gene expression in B-cells derived from chronic lymphocyte leukemia (CLL) patients.^[28] Zhang *et al.* showed that AA genotype of -938C>A is positively associated with increased breast cancer susceptibility in Chinese population.^[29,30] However, some reports indicated no significant association between *BCL2* gene expression and -938C>A allelic variants.^[31] In this report, we studied the association between -938C>A allelic variants and breast cancer risk of women in Mazandaran province at Northern Iran.

MATERIALS AND METHODS

Cases and controls

This case-control study involved 120 patients who underwent surgery in some referenced hospitals in Mazandaran province from September 2012 to December 2014. Patients' age ranged from 29 to 72 years. Demographic and clinicopathological data were extracted from patients' record available in

hospitals. A group of 130 healthy females ranging from 26 to 79 years were also included in this study to investigate whether certain -938C>A genotype is a susceptible marker. Five milliliters peripheral blood was collected from both patients and control group and stored at -80°C.

DNA extraction and polymerase chain reaction amplification

Blood samples were collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes, and genomic DNA was extracted from blood lymphocytes by proteinase K/SDS digestion and phenol-chloroform extraction method.^[20] DNA concentration was measured spectrophotometrically, and its purity was checked through agarose gel electrophoresis. A 253 bp fragment containing - 938C/A allelic variant was amplified using forward: 5-TTATCCAGCAGCTTTTCGG-3 and reverse: 5-GGCGGCAGATGAATTACAA-3 primers. Polymerase chain reaction (PCR) amplification performed in 25 µl reaction containing 1X PCR buffer, 100 ng genomic DNA, 1.5 mM MgCl₂, 0.3 mM each forward and reverse primers, 0.2 µM dNTPs, and 2.5 U taq DNA polymerase (10 U/µl). The cycling conditions including an initial denaturation at 94°C for 4 min, 32 cycles of denaturation at 94°C for 40 s, annealing at 52°C for 35 s, and extension at 72°C for 37 s and a final extension at 72°C for 7 min. Products were analyzed by electrophoresis at 1.5% agarose gel and visualized by ethidium bromide staining.

-938C>A genotyping

The -938C>A genotype of *BCL2* P2 promoter was determined using single-strand conformation polymorphism (SSCP) analysis. The amplified fragments were purified using GF-1 Gel DNA Recovery (extraction) Kit (Vivantis, Malaysia) according to manufacturer's instruction and their concentration determined by spectrophotometer. Equal amount of each sample (approximately 1 µl) was added to 9 µl of denaturing solution (95% formamide, 20 mM EDTA pH 8.0, 0.05% bromophenol blue, and 0.05% xylene cyanol), boiled for 10 min, and immediately chilled on ice. Electrophoresis performed in a 12% nondenaturing acrylamide gel at 350 volts for 3 h. The gel was visualized after silver staining, and the genotypes were determined based on resulting banding pattern.^[32] Two samples of each SSCP profiles were gel-purified and sequenced in Bioneer company (South Korea) to verify the results of genotyping.

Statistical and sequence analysis

The genotype and allele frequency of -938C>A genotype were tested for Hardy-Weinberg equilibrium (HWE) for both patient and control group using Chi-square test. Odds ratio (OR), confidence intervals (CIs), and *P* values were calculated using unconditional logistic regression and adjusted for age to estimate the association between genotypes and the risk of breast cancer or some demographic and

clinicopathological data. Data analysis carried out by SAS 9.1 statistics software (The SAS Institute, NC, USA) and $P < 0.05$ was considered statistically significant.^[33] Nucleotide sequence analysis performed by BioEdit 7.9.1 program. The acquired sequences were compared with those available in databases using basic local alignment search tool (BLAST) program and alignment done by ClustalW method.^[34]

RESULTS

Demographic and clinicopathological data

This study performed on 120 breast cancer patients and 130 healthy controls with known demographic and clinicopathological data [Table 1] that belong to Mazandaran province in Northern Iran. The mean age of patient and healthy individuals was 47.13 ± 8.4 years and 46.5 ± 7.2 years, respectively, and Student's *t*-test showed no significant relationships between two groups ($P = 0.312$). Results of Chi-square test showed that the genotype frequency of case and control groups did not significantly diverge from HWE (both $P > 0.05$). Demographic data analysis indicated that only 10% of patients had a positive familial history and just 7% of them belonged to smoker group. Pathologic information demonstrated that 93.7% of patients were diagnosed at Grade II and III and 58% of them were at advanced stage when the disease detected for the first time.

The -938C>A genotype distribution and its association to known clinicopathological data

A single DNA band was appeared in 1% agarose gel following PCR amplification [Figure 1]. SSCP analysis

showed that three distinct profiles were appeared in acrylamide gel [Figure 2]. Results of nucleotide sequencing and sequence database searches by the on-line BLAST tool confirmed them as belong to *BCL2* gene P2 promoter. Nucleotide sequence analysis of the amplified fragments each having unique SSCP profile with BioEdit program determined the presence of variant alleles at nucleotide position -938C>A [Figure 3]. The -938C>A genotype of all samples was subsequently determined according to known SSCP profiles and resulting genotype distribution was presented in Table 2. Results showed that the allelic frequency of AA, AC, and CC genotypes was 10%, 62%,




Figure 1: Electrophoresis of the amplified fragment of B-cell lymphoma 2 P2 promoter in 2% agarose gel. 1, 2: 253 bp fragment; 3: 100 bp DNA ladder (fermentas)

Table 1: The demographic and clinicopathological characteristics of patients^a

Clinicopathological variables	Number of patient (%)
Age	
≤45	45 (46)
>45	53 (54)
Menopause	
Positive	43 (44)
Negative	55 (56)
Grade	
I	6 (6.2)
II	56 (58.3)
III	34 (35.4)
TNM staging	
I-II	32 (42)
III-IV	44 (58)
Family history	
Positive	11 (10)
Negative	99 (90)
Smoking	
Positive	8 (7)
Negative	106 (93)

^aNumbers and percentages of patients who their characteristics were available. TNM=Tumor node metastasis




Figure 2: Single-strand conformation polymorphism profile of the amplified 253 bp fragment of B-cell lymphoma 2 P2 promoter in 12% nondenaturing acrylamide gel. 1, 2: CC genotype; 3, 4: AC genotype; 5, 6: AA genotype




Figure 3: Sequencing profile of three allelic variants of the position -938C>A of *BCL2* gene. (a) AC genotype; (b) CC genotype; (c) AA genotype

and 28% for case and 28%, 50%, and 22% in control group, respectively. As shown in Table 2, in logistic regression model, *BCL2* -938C/A variant genotype AA was significantly associated ($P = 0.041$) with a decreased risk of breast cancer by 0.31-fold (OR = 0.31, CI = 0.091–0.909) compared to CC genotype. The variant genotypes AA and AC + CC were not significantly correlated with demographic and clinicopathological characteristics including age at diagnosis ($P = 0.69$), menopause ($P = 0.357$), grade ($P = 0.89$), smoking ($P = 0.777$), and family history ($P = 0.357$) [Table 3].

DISCUSSION

The incidence rate of breast cancer has dramatically increased since last decade in Iran and it is now one of the

most common female malignant tumors.^[4] Antiapoptotic *BCL2* protein involves in mitochondrial pathway of apoptosis through cell cycle arrest which is commonly led to patients survival. Nevertheless, its increased expression was denoted to be associated with unfavorable outcome in some cancer types.^[15-17] The *BCL2* gene -938C>A SNP initially identified by Park *et al.* have also been reported to be controversially involved in CLL development. However, consistent results were reported regarding to its association with solid tumors development such as breast cancer.^[22-25] We conducted a case-control population-based study to determine the *BCL2* gene -938C>A allelic variants and its association with breast cancer risk or clinicopathological features in Mazandaran province at Northern Iran. The mean age of breast cancer patients in this study was 47.13 ± 8.4 years which is consistent with the results of

Table 2: Distribution of -938C>A polymorphisms of B-cell lymphoma 2 P2 promoter and its association to breast cancer risk

Genotype	Number of subjects (%)		Nonadjusted ^a		P	Adjusted ^b	
	Case	Control	P	OR		OR	CI
AA	12 (10)	36 (28)	-	1			
AC	74 (62)	65 (50)	0.0337	0.288	0.041	0.31	0.091-0.909
CC	34 (28)	29 (22)	0.0537	0.281	0.063	0.3	0.077-1.02
AC+CC	108 (90)	94 (72)	-	1			
AA	12 (10)	36 (28)	0.0559	0.345	0.065	0.365	0.116-1.027
AC+AA	86 (72)	101 (78)	-	1			
CC	34 (28)	29 (22)	0.4893	1.379	0.51	1.35	0.555-3.427
AA+CC	46 (38)	65 (50)	-	1			
AC	74 (62)	65 (50)	0.228	1.632	0.32	1.58	0.736-3.616
Total	120	130					

^aLogistic regression model, nonadjusted, ^bLogistic regression model, adjusted for diagnostic age. OR=Odds ratio, CI=Confidence interval

Table 3: Relationship between -938 C>A allelic variants of B-cell lymphoma 2 P2 promoter and known clinicopathological variables

Clinicopathological variables	All	Genotype (%)		P	Adjusted ^a	
		AA	AC+CC		OR	CI
Age						
≤45	45 (46)	4 (8.9)	41 (91.1)	-	1	-
>45	53 (54)	6 (11.3)	47 (88.7)	0.69	1.3	0.345-4.96
Menopause						
Negative	43 (44)	3 (7)	40 (93)	-	1	-
Positive	55 (56)	7 (12.7)	48 (87.3)	0.357	1.94	0.472-8.01
Grade						
I-II	62 (64.6)	5 (8.1)	57 (91.9)	-	1	-
III	34 (35.4)	3 (8.8)	31 (91.2)	0.89	1.1	0.247-4.928
TNM staging						
I-II	32 (42)	3 (9.4)	29 (90.4)	-	1	-
III-IV	44 (58)	4 (10)	40 (90.9)	0.966	0.967	0.201-4.653
Family history						
Negative	11 (10)	2 (18.2)	9 (81.8)	-	1	-
Positive	99 (90)	9 (9.1)	90 (90.1)	0.357	0.455	0.085-2.438
Smoking						
Negative	8 (7)	1 (12.3)	7 (87.5)	-	1	-
Positive	106 (93)	10 (9.4)	96 (90.6)	0.777	0.729	0.081-6.536

^aLogistic regression model adjusted for diagnostic age. All statistical tests were two-sided with a significance of $P < 0.05$. OR=Odds ratio; CI=Confidence interval; TNM=Tumor node metastasis

other researches in Iran and verifying again the younger age of breast cancer development for Iranian women.^[35,36] Numerous reports have highlighted positive association between familial disease history or smoking habit and cancer incidence. However, in this study, only 10% of cases appeared to have positive disease history and just 7% of them belonged to smoker group. Most patients were identified to be at Grades II (58.3%) and III (35.4%) and Stages III and IV (58%) when disease was firstly diagnosed. Similar results were also reported in a research conducted on a group of 3085 women with breast cancer in Iran.^[36] These reports highlight that cultural and social issues, lifestyle change, and reproductive behaviors are among key factors for developing different clinicopathological features in Iranian women. Breast self-examination and regular evaluations may be helpful for screening of the disease at primary stage.^[37] Genotype frequency of *BCL2* gene -938C>A SNP studied using PCR-SSCP analysis confirmed the presence of three AA, AC, and CC genotypes in both cases and healthy controls. Statistical analysis by logistic regression model showed that the variant genotype AA was significantly associated ($P = 0.041$) with a decreased risk of breast cancer by 0.31-fold (OR = 0.31, CI = 0.091–0.909). Previous researches conducted on the association between -938C>A polymorphism and cancer susceptibility including CLL and breast cancer reported positive association between AA genotype and favorite outcome for patients survival.^[23,28,38] However, study of -938C>A polymorphism in breast cancer patients of Chinese Mainland showed that the homozygous AA genotype is associated with an increased risk of breast cancer development by 2.37-fold. Overall, these results emphasize that the *BCL2* (-938C>A) AA genotype can serve as a susceptible factor in breast cancer. However, its association with disease incidence either positive or negative remained to be elucidated and complementary results are needed to confirm whether *BCL2* (-938C>A) allelic variants can serve as a prognostic biomarker for breast cancer patients. The study of the relationship between *BCL2* (-938C>A) genotype and clinicopathological characteristics such as age, menopause, smoking, family history, and stage of cancer in this study demonstrated no significant correlation. The study of the association between *BCL2* (-938C>A) allelic variants and clinicopathological features did not create consistent results.^[21,30,37] The discrepancy between the results of the clinicopathological properties and the association between SNP and breast cancer risk may be due to several factors including difference in ethnicity, diet, geographical variation, and environmental exposures.^[31,39] Particularly, the effects of pesticides on disease incidence should be studied with more priority as it is massively applied in Northern Iran.^[8] Further researches, conducted on a larger group, are needed to clarify these points.

CONCLUSIONS

This population-based case-control study performed on 120 breast cancer patients and 130 healthy women as control to determine -938C>A allelic variants of *BCL2* P2 promoter in Mazandaran province at Northern Iran. Results showed that AA genotype of *BCL2* gene (-938C>A) is associated with decreased susceptibility to breast cancer. No significant correlation found between -938C>A genotype and clinicopathological data. Hence, investigating the -938C>A SNP of *BCL2* gene promoter could be an appropriate molecular marker to determine individual sensitivity to breast cancer.

Financial support and sponsorship

This project is partly supported by a grant from Sari Agricultural Sciences and Natural Resources University.

Conflicts of interest

There are no conflicts of interest.

AUTHORS' CONTRIBUTION

AB and SEM contributed in the conception of the work, revising the draft, approval of the final version of the manuscript, and agreed for all aspects of the work. NN performed surgery and provided samples.

REFERENCES

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. *CA Cancer J Clin* 2005;55:74-108.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, *et al.* Cancer statistics, 2008. *CA Cancer J Clin* 2008;58:71-96.
3. Goya M. Iranian Annual Cancer Registration Report 2005/2006. Ministry of Health and Medical Education, Health Deputy, Center for Disease Control and Prevention, Tehran, Iran; 2007.
4. Sadjadi A, Malekzadeh R, Derakhshan MH, Sepehr A, Nouraie M, Sotoudeh M, *et al.* Cancer occurrence in Ardabil: Results of a population-based cancer registry from Iran. *Int J Cancer* 2003;107:113-8.
5. Khadivi R, Harrirchi I, Akbari ME. Ten year breast cancer screening and follow up in 52200 women in Shahre-Kord, Iran (1997-2006). *Iran J Cancer Prev* 2012;1:73-7.
6. Colditz GA. Epidemiology of breast cancer. Findings from the nurses' health study. *Cancer* 1993;71 4 Suppl: 1480-9.
7. Perera FP, Estabrook A, Hewer A, Channing K, Rundle A, Mooney LA, *et al.* Carcinogen-DNA adducts in human breast tissue. *Cancer Epidemiol Biomarkers Prev* 1995;4:233-8.
8. Shokrzadeh M, Karami M, Ghadi MA. Measuring organophosphorus insecticide residue in rice produced in Amol, North of Iran. *J Mazandaran Univ Med Sci* 2013;23:215-21.
9. Norbury CJ, Hickson ID. Cellular responses to DNA damage. *Annu Rev Pharmacol Toxicol* 2001;41:367-401.
10. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. *Surg Oncol* 1997;6:133-42.
11. Kamesaki H. Mechanisms involved in chemotherapy-induced

- apoptosis and their implications in cancer chemotherapy. *Int J Hematol* 1998;68:29-43.
12. Hirata H, Hinoda Y, Kikuno N, Suehiro Y, Shahryari V, Ahmad AE, *et al.* Bcl2 -938C/A polymorphism carries increased risk of biochemical recurrence after radical prostatectomy. *J Urol* 2009;181:1907-12.
 13. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. *Nat Rev Cancer* 2002;2:647-56.
 14. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, *et al.* Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. *EMBO J* 1988;7:123-31.
 15. Faderl S, Keating MJ, Do KA, Liang SY, Kantarjian HM, O'Brien S, *et al.* Expression profile of 11 proteins and their prognostic significance in patients with chronic lymphocytic leukemia (CLL). *Leukemia* 2002;16:1045-52.
 16. Keshgegian AA, Johnston E, Cnaan A. Bcl-2 oncoprotein positivity and high MIB-1 (Ki-67) proliferative rate are independent predictive markers for recurrence in prostate carcinoma. *Am J Clin Pathol* 1998;110:443-9.
 17. Stackhouse GB, Sesterhenn IA, Bauer JJ, Mostofi FK, Connelly RR, Srivastava SK, *et al.* p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. *J Urol* 1999;162:2040-5.
 18. Young RL, Korsmeyer SJ. A negative regulatory element in the bcl-2 5'-untranslated region inhibits expression from an upstream promoter. *Mol Cell Biol* 1993;13:3686-97.
 19. Rossi D, Rasi S, Capello D, Gaidano G. Prognostic assessment of BCL2-938C>A polymorphism in chronic lymphocytic leukemia. *Blood* 2008;111:466-8.
 20. Zenz T, Benner A, Dührsen U, Dürig J, Döhner H, Siffert W, *et al.* BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia. *Leuk Lymphoma* 2009;50:1837-42.
 21. Bachmann HS, Heukamp LC, Schmitz KJ, Hilburn CF, Kahl P, Buettner R, *et al.* Regulatory BCL2 promoter polymorphism (-938C>A) is associated with adverse outcome in patients with prostate carcinoma. *Int J Cancer* 2011;129:2390-9.
 22. Heubner M, Wimberger P, Otterbach F, Kasimir-Bauer S, Siffert W, Kimmig R, *et al.* Association of the AA genotype of the BCL2 (-938C>A) promoter polymorphism with better survival in ovarian cancer. *Int J Biol Markers* 2009;24:223-9.
 23. Bachmann HS, Otterbach F, Callies R, Nüchel H, Bau M, Schmid KW, *et al.* The AA genotype of the regulatory BCL2 promoter polymorphism (-938C>A) is associated with a favorable outcome in lymph node negative invasive breast cancer patients. *Clin Cancer Res* 2007;13:5790-7.
 24. Hirata H, Hinoda Y, Nakajima K, Kikuno N, Suehiro Y, Tabatabai ZL, *et al.* The bcl2-938CC genotype has poor prognosis and lower survival in renal cancer. *J Urol* 2009;182:721-7.
 25. Lehnerdt GF, Franz P, Bankfalvi A, Grehl S, Kelava A, Nüchel H, *et al.* The regulatory BCL2 promoter polymorphism (-938C>A) is associated with relapse and survival of patients with oropharyngeal squamous cell carcinoma. *Ann Oncol* 2009;20:1094-9.
 26. Ruiz-Llorente S, Montero-Conde C, Milne RL, Moya CM, Cebrián A, Letón R, *et al.* Association study of 69 genes in the ret pathway identifies low-penetrance loci in sporadic medullary thyroid carcinoma. *Cancer Res* 2007;67:9561-7.
 27. Park BL, Kim LH, Cheong HS, Cho HY, Kim EM, Shin HD, *et al.* Identification of variants in cyclin D1 (CCND1) and B-Cell CLL/Lymphoma 2 (BCL2). *J Hum Genet* 2004;49:449-54.
 28. Nüchel H, Frey UH, Bau M, Sellmann L, Stanelle J, Dürig J, *et al.* Association of a novel regulatory polymorphism (-938C>A) in the BCL2 gene promoter with disease progression and survival in chronic lymphocytic leukemia. *Blood* 2007;109:290-7.
 29. Masago K, Togashi Y, Fujita S, Nagai H, Sakamori Y, Okuda C, *et al.* Effect of the BCL2 gene polymorphism on survival in advanced-stage non-small cell lung cancer patients who received chemotherapy. *Oncology* 2013;84:214-8.
 30. Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, *et al.* BCL-2 (-938C>A) polymorphism is associated with breast cancer susceptibility. *BMC Med Genet* 2011;12:48.
 31. Azubuike SO, Celestina UO. Breast cancer: The perspective of Northern Nigerian women. *Int J Prev Med* 2015;6:130.
 32. Beidler JL, Hilliard PR, Rill RL. Ultrasensitive staining of nucleic acids with silver. *Anal Biochem* 1982;126:374-80.
 33. Breslow NE, Day NE. *Statistical Methods in Cancer Research. Vol. 2.* Lyon: International Agency for Research on Cancer; 1987. p. 89-97.
 34. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol* 1990;215:403-10.
 35. Harirchi I, Kolahdoozan S, Karbakhsh M, Chegini N, Mohseni SM, Montazeri A, *et al.* Twenty years of breast cancer in Iran: Downstaging without a formal screening program. *Ann Oncol* 2011;22:93-7.
 36. Sadjadi A, Nouraie M, Ghorbani A, Alimohammadian M, Malekzadeh R. Epidemiology of breast cancer in the Islamic Republic of Iran: First results from a population-based cancer registry. *East Mediterr Health J* 2009;15:1426-31.
 37. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: A review of 903 case records. *Public Health* 2000;114:143-5.
 38. Majid A, Tsoulakis O, Walewska R, Gesk S, Siebert R, Kennedy DB, *et al.* BCL2 expression in chronic lymphocytic leukemia: Lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. *Blood* 2008;111:874-7.
 39. Neamatzadeh H, Shiryazdi SM, Kalantar SM. BRCA1 and BRCA2 mutations in Iranian breast cancer patients: A systematic review. *J Res Med Sci* 2015;20:284-93.